‘India cancels licences of some drug firms in crackdown on fake products’


Share post:

Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for selling adulterated or fake products, a government source said on Thursday.

India is known as the ‘pharmacy of the world’ and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22.

But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan  in Uzbekistan last year linked to drugs made by India-based pharmaceutical companies.

Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken.

“There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared,” Mandaviya told reporters at an event.

Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had direct knowledge of the matter, told Reuters news agency.

The source, who did not want to be identified as they were not authorized to speak to the media, declined to reveal the names of the companies.

The government has said it will spend $79.6 million on strengthening its drug regulatory after the World Health Organization raised concerns about domestically produced cough syrups being linked to the death of children in Gambia and Uzbekistan.


Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

MHRA grants authorisation for LEO Pharma’s Adtralza 2 mL pen solution

The Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the marketing authorisation of Adtralza, a dermatological solution...

Grundon launches maiden UK-wide inhaler recycling programme

Grundon Waste Management has introduced what it claims to be the UK's first verified nationwide inhaler return and...

‘Record fine imposed on hydrocortisone manufacturers for dominant position abuse and 10,000% price increase’

The Competition Appeal Tribunal (CAT) has upheld the Competition and Markets Authority’s (CMA) findings against two pharmaceutical manufacturers...

Vision Report: Legal reforms, adequate funding imperative for success of community pharmacy

Achieving the community pharmacy vision necessitates legal adjustments and additional funding beyond recent boosts, the pharmacy vision document...